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Objective: To assess whether use of oral glucocorticoids is associated with cardiovascular and
cerebrovascular morbidity.
Design and setting: Nested case–control study within a cohort of patients (> 50 years old) with at least
one prescription for oral or non-systemic glucocorticoids. Data were from the general practice research
database.
Patients: 50 656 patients were identified with a first record for ischaemic heart disease (International
classification of diseases, ninth revision (ICD-9) codes 410, 411, 413, and 414), ischaemic stroke or
transient ischaemic attack (ICD-9 codes 430–436), or heart failure (ICD-9 code 428) between 1988 and
1998. One control was matched to each case by sex, age, general practice, underlying disease, and
calendar time.
Main outcome measure: Odds ratio (OR) of cardiovascular or cerebrovascular events in patients using
oral glucocorticoids compared with non-users.
Results: There was a significant association between ever use of oral glucocorticoids and any
cardiovascular or cerebrovascular outcome (adjusted OR 1.25, 95% confidence interval (CI) 1.21 to
1.29). The association was stronger for current use of oral glucocorticoids than for recent or past use.
Among current users, the highest ORs were observed in the group with the highest average daily dose,
although the dose–response relation was not continuous. Current use was associated with an increased
risk of heart failure (adjusted OR 2.66, 95% CI 2.46 to 2.87), which was consistent between patients with
rheumatoid arthritis, patients with chronic obstructive pulmonary disease, and patients without either of the
two conditions. Also, current use was associated with a smaller increased risk of ischaemic heart disease
(OR 1.20, 95% CI 1.11 to 1.29).
Conclusions: Oral glucocorticoid use was identified as a risk factor for heart failure. However, the
evidence remains observational and only a randomised controlled trial of glucocorticoid treatment versus
other disease modifying agents is likely to distinguish the importance of the underlying disease activity
from its treatment in predicting cardiovascular outcomes.
G
lucocorticoids are widely prescribed drugs in modern
medicine. Data from the UK suggest that nearly 1% of
the total adult population use oral glucocorticoids.1
Use of oral glucocorticoids has been associated with the
occurrence of side effects, such as increased risk of fracture,2
but there is also concern with respect to metabolic and
cardiovascular morbidity and mortality.3 4 In addition,
glucocorticoid use has been shown to be associated with
fluid retention, which is induced by an enhanced sodium
reabsorption and expansion of the extracellular fluid
volume.5 Also, patients with Cushing’s syndrome have an
increased risk of obesity, hypertension, hyperglycaemia, and
premature death caused by high plasma concentrations of the
endogenous glucocorticoid cortisol.6 There is also evidence
that, even among men with cortisol secretion within the
‘‘normal’’ range, hypercortisolism is associated with risk
factors for cardiovascular and cerebrovascular outcomes,
including hypertension, hyperglycaemia, and dyslipidae-
mia.7–14 However, not all patients with these risk factors
develop cardiovascular and cerebrovascular diseases. Indeed,
atherosclerosis is increasingly recognised as an inflammatory
condition of the blood vessel wall.15 Glucocorticoids have
anti-inflammatory and antiproliferative actions in vessels,16 17
which may counteract their adverse effects on systemic
cardiovascular and cerebrovascular risk factors.
Against this background, it has yet to be established
whether use of exogenous glucocorticoids is associated with
an increased risk of cardiovascular and cerebrovascular
morbidity. Very few randomised controlled trials have ever
been performed with oral glucocorticoid treatment and none
has been powered to detect differences in cardiovascular
events.18 Some of the disorders for which glucocorticoids are
commonly prescribed are themselves associated with cardio-
vascular disease. Patients with rheumatoid arthritis (RA) or
chronic obstructive pulmonary disease (COPD) have an
increased risk of cardiovascular mortality due to the systemic
effect of the disease, regardless of the medications they
used.19–23 However, it is unclear whether use of glucocorti-
coids contributes to these associations.
Hence, the objective of this study was to quantify the
association between use of oral glucocorticoids and cardio-
vascular and cerebrovascular morbidity in a nested case–
control study. Data were obtained from the general practice
research database (GPRD).
Abbreviations: BMI, body mass index; CI, confidence interval; COPD,
chronic obstructive pulmonary disease; GPRD, general practice research
database; ICD-9, International classification of diseases, ninth revision;






General practitioners have a key role in the health care
system in the UK, as they are responsible for primary health
care and specialist referrals. Patients are semipermanently
affiliated to a practice, which centralises the medical
information not only from the general practitioners them-
selves but also from specialist referrals and hospitalisations.
The current study drew data from 683 practices in various
geographical areas in the UK registered on the GPRD.
The GPRD covers a population of about 3.5 million men
and women. The data recorded on the GPRD include
demographic information, prescription data, clinical events,
preventive care provided, specialist referrals, hospital admis-
sions, and their major outcomes.24 Clinical data are stored
and retrieved by means of the Oxford medical information
system and read codes for diseases that are cross referenced
to the International classification of diseases, ninth revision
(ICD-9). Each entry on the GPRD is internally validated by
cross checking within the practice and by comparisons with
external statistics.24 Only data from practices that pass this
quality control are compiled and are part of the GPRD.
Several independent validation studies have confirmed a
high level of completeness and validity of the GPRD, which is
owned by the Department of Health in the UK.25
Study population
From the GPRD, we identified all permanently registered
patients aged 50 years and older with at least one prescription
for oral glucocorticoids during the time from the enrolment
date of their practice in the GPRD (data collection started in
1988) to the end of the study period (31 December 1997), as
well as patients who received at least one prescription for
non-systemic glucocorticoids (topical, aural, ophthalmic, or
nasal) but not for systemic glucocorticoids. Use of inhaled
steroids was also allowed for patients using oral glucocorti-
coids. The date of the first corticosteroid prescription marked
the start of follow up. The follow up of the patient stopped
when the patient died or was lost to follow up, at the
occurrence of an event (see list of events below), or at the end
of the study period (December 1997), whichever occurred
first.
Documented prescription is a means of ensuring active
registration of participants in GPRD. To avoid biasing the
results by inclusion of patients for whom data collection was
incomplete, all participants were required to receive at least
one prescription for glucocorticoids during the study period.
Definit ion of cases and controls
Within the cohort of glucocorticoid users, a nested case–
control study was conducted. Cases were defined as patients
with a first record of ischaemic heart disease (ICD-9 code
410, 411, 413, 414), heart failure (ICD-9 code 428), or
ischaemic stroke or transient ischaemic attack (ICD-9 code
430–436) during follow up. The date of the first event during
follow up was the index date for the cases. For each case, one
control was matched on sex, year of birth, general practice,
presence of underlying disease, and calendar time. When no
eligible control was found, the matching criterion with
respect to year of birth was relaxed (to ¡3 years). When it
was still impossible to find a suitable control, a control from
another practice was chosen. Controls were eligible for
inclusion if they had no record of ischaemic heart disease,
cerebrovascular events, or heart failure at any time.
Because of the possible association between indications for
glucocorticoids and cardiovascular disease, cases and controls
were matched for the presence or absence of these underlying
diseases. Patients in the case and control groups were
classified as having RA (ICD-9 code 714.0) if they had RA
diagnosed before the index date, and were classified as
having COPD or allied conditions (ICD-9 codes 490–496) if
they had COPD diagnosed before the index date. The date of
the first recording of RA or COPD diagnosis was used to
estimate the duration of disease. Patients without recorded
diagnoses of RA or COPD were included only if they were not
using prescription drugs indicating the presence of either
disease. Patients who had both diagnoses of RA and COPD
contributed to both the RA group and the COPD group.
Exposure assessment
For each patient, we identified all prescriptions for oral
(systemic) glucocorticoids (cortisone, hydrocortisone, pred-
nisone, prednisolone, triamcinolone, methylprednisone,
dexamethasone, and betamethasone) between entry into
the cohort and the index date. Several indices of oral
glucocorticoid exposure were calculated. Exposure was
categorised dichotomously according to whether oral gluco-
corticoids had been prescribed before the index date.
Exposure was also classified according to timing of use in
relation to the index date: ‘‘current use’’ was defined as any
prescription of oral glucocorticoids in the three month period
before the index date; ‘‘recent use’’ was defined as having no
prescription in the three month period before the index date
and a prescription one year before the index date; and ‘‘past
use’’ was defined as no prescriptions during one year before
the index date. Oral glucocorticoid doses were calculated as
prednisolone equivalent doses, where 5 mg prednisolone was
equivalent to 25 mg cortisone, 20 mg hydrocortisone, 5 mg
prednisone, 4 mg triamcinolone, 4 mg methylprednisone,
750 mg dexamethasone, or 750 mg betamethasone. The
average daily dose of oral glucocorticoids for current, recent,
and past users was calculated from data on the prescribed
daily dose that was available from the general practitioner
records. The average daily dose was classified as missing if
less than 50% of the prescribed daily doses for the patient
were not recorded on the database. The cumulative dose was
obtained by summing all doses and was classified as missing
when one or more doses were not registered on the database.
Assessment of potential confounders
Potential confounders in this study were medical conditions
and drugs that have been associated with an increased or
decreased risk of cardiovascular and cerebrovascular disease.
To address confounding by co-prescription of other drugs, we
assessed use of antihypertensive drugs (diuretics, b blockers,
angiotensin converting enzyme inhibitors, calcium channel
blockers, or other), use of lipid lowering drugs (fibrates or
statins), nitrates, cardiac glycosides, antiplatelet drugs, oral
anticoagulants, and antiarrhythmics, as well as use of
insulin, oral hypoglycaemic drugs, and hormone replacement
therapy in the year before the index date. In addition, we
assessed the use of other drugs indicated for the treatment of
RA (non-steroidal anti-inflammatory drugs (NSAIDs) and
disease modifying anti-rheumatic drugs) and lung disease
(bronchodilators, cromoglycates) in the year before the index
date.
Confounding by disease indication was addressed by
examining consistency of effects in cases and controls
matched for RA, COPD, and other indications. The number
of physician visits (general practitioner or specialist) and
number of hospital admissions in the year before the start of
glucocorticoid use were also considered as markers for
patients’ health status. Further, we evaluated the effect of
smoking and body mass index (BMI).
Data analysis
The strength of the association between use of oral
glucocorticoids and the occurrence of outcome events
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(ischaemic heart disease, stroke/transient ischaemic event,
and heart failure) was estimated by conditional logistic
regression analysis and expressed as crude and adjusted odds
ratios (OR) and 95% confidence intervals (CI). Covariates
were included in the regression model if they were either
independently significantly associated with the outcome or
induced a 10% or greater change in the crude matched OR for
oral corticosteroid use.26 In addition, ischaemic heart disease,
heart failure, and cerebrovascular events were analysed
separately. Patients with RA, patients with COPD, and
patients without either of these conditions were analysed as
subgroups. As entering information on BMI and smoking is
optional for the general practitioner, data were analysed on
patients with complete information only, as well as on all
patients with the use of an indicator for missing data. As the
results of both analyses were not different, BMI and smoking
of all patients were adjusted for in the final analyses.
RESULTS
The study population comprised 50 656 patients and an equal
number of matched controls. Table 1 lists the characteristics
of the study population. The majority were women (56.7%)
and about 85% were aged between 60–90 years. There were
1515 case–control pairs matched for diagnosis of RA (median
duration of disease among cases and controls 7.2 years and
6.8 years, respectively), 16 440 case–control pairs matched for
diagnosis of asthma or COPD (median duration 3.7 years for
both cases and controls), and 31 240 case–control pairs
without a diagnosis of RA or COPD. High BMI and smoking
were significantly more frequent among the cases than
among controls, as was the prevalence of prescription drug
use in the year before the index date. The most frequently
used drugs were NSAIDs, diuretics, bronchodilators, and b
blockers. Further, the numbers of hospital admissions and
general practitioner visits in the year before the index date
were higher among cases than among controls.
Table 2 shows the association between the use of oral
glucocorticoids and the risk of any cardiovascular or
cerebrovascular outcome. The prevalence of using oral
glucocorticoids before the index date was higher among the
cases (30.3%) than among controls (26.4%), yielding a crude
OR of 1.31 (95% CI 1.27 to 1.35). This relation persisted after
adjusting for use of NSAIDs, hormone replacement therapy,
antihypertensive drugs, nitrates, oral anticoagulants, anti-
platelet drugs, antidiabetic drugs, bronchodilators, cromogly-
cates, inhaled steroids, disease modifying antirheumatic
drugs, smoking, and BMI (adjusted OR 1.25, 95% CI 1.21
to 1.29). The association was stronger for current use of oral
Table 1 Characteristics of cases and matched controls
Characteristics Cases (n = 50656) Controls (n = 50656) Crude OR (95% CI)
Sex
Male 21 952 (43.3%) 21 952 (43.3%) NA
Female 28 704 (56.7%) 28 704 (56.7%) NA
Age (years)
50–59 4 884 (9.6%) 4 950 (9.8%) NA
60–69 12 177 (24.0%) 12 361 (24.4%) NA
70–79 18 129 (35.8%) 18 296 (36.1%) NA
80–89 13 036 (25.7%) 12 742 (25.2%) NA
>90 2 430 (4.8%) 2 307 (4.6%) NA
Matching by disease indication
RA 1 515 (3.0%) 1 515 (3.0%) NA
COPD 16 440 (32.5%) 16 440 (32.5%) NA
Other* 31 240 (61.7%) 31 240 (61.7%) NA
Body mass index (kg/m2)
,20 1 872 (3.7%) 2 101 (4.1%) 1.00 (reference)
20–25 11 256 (22.2%) 12 235 (24.2%) 0.96 (0.90 to 1.03)
25–30 12 207 (24.1%) 11 831 (23.4%) 1.13 (1.09 to 1.17)
>30 5 779 (11.4%) 4 569 (9.0%) 1.39 (1.33 to 1.46)
Unknown 19 542 (38.6%) 19 920 (39.3%) 1.05 (1.02 to 1.09)
Smoking
Yes 9 997 (19.7%) 8 609 (17.0%) 1.20 (1.16 to 1.24)
Unknown 13 719 (27.1%) 14 940 (29.5%) 0.90 (0.87 to 0.93)
Use of prescription drugs in the year before the index date
NSAIDs 14 415 (28.5%) 12 694 (25.1%) 1.20 (1.16 to 1.23)
DMARDs 265 (0.5%) 255 (0.5%) 1.05 (0.87 to 1.26)
HRT 1 169 (2.3%) 1 236 (2.4%) 0.93 (0.85 to 1.02)
Bronchodilators 9 870 (19.5%) 8 737 (17.2%) 1.28 (1.23 to 1.33)
Antidiabetic drugs 2 681 (5.3%) 1 371 (2.7%) 2.02 (1.89 to 2.16)
Cardiac glycosides 2 093 (4.1%) 962 (1.9%) 2.26 (2.09 to 2.44)
Antihypertensive drugs 19 464 (38.4%) 13 964 (27.6%) 1.68 (1.63 to 1.72)
Nitrates 1 735 (3.4%) 435 (0.9%) 4.10 (3.69 to 4.57)
Oral anticoagulants 4.371 (8.6%) 3 224(6.4%) 1.42 (1.35 to 1.49)
Antiplatelet drugs 285 (0.6%) 139 (0.3%) 2.07 (1.69 to 2.54)
Lipid lowering drugs 374 (0.7%) 302 (0.6%) 1.24 (1.07 to 1.45)
Antiarrhythmics 783 (1.5%) 439 (0.9%) 1.80 (1.60 to 2.02)
Number of hospital admissions in year before index date
None 44 480 (87.8%) 45 151 (89.1%) 1.00 (reference)
1 4 019 (7.9%) 3 774 (7.5%) 1.08 (1.04 to 1.14)
.1 2 157 (4.3%) 1 731 (3.4%) 1.27 (1.19 to 1.36)
Number of visits to a general practitioner in year before index date
None 44 480 (87.8%) 45 151 (89.1%) 1.00 (reference)
1 4 019 (7.9%) 3 774 (7.5%) 1.21 (1.06 to 1.40)
.1 2 157 (4.3%) 1 731 (3.4%) 1.77 (1.40 to 2.23)
*Patients without a diagnosis of RA or lung disease but with use of disease specific drugs for RA or COPD were
excluded (n = 1940 case–control pairs excluded).
CI, confidence interval; COPD, chronic obstructive pulmonary disease; DMARDs, disease modifying anti-rheumatic
drugs; HRT, hormone replacement therapy; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs;
OR, odds ratio; RA, rheumatoid arthritis.
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glucocorticoids than for recent or past use. Among current
users, the highest ORs were observed in the group with the
highest average daily dose, although the dose–response
relation was not continuous. There was no clear association
with cumulative dose.
Analysis according to the type of outcome event indicated
that current use of oral glucocorticoids was associated with
an increased risk for heart failure (adjusted OR 2.66, 95% CI
2.46 to 2.87) (table 3). Further, current use of oral
glucocorticoids was associated with an increased risk for
ischaemic heart disease events (adjusted OR 1.20, 95% CI
1.11 to 1.29) but was associated with a decreased risk for
cerebrovascular disease (adjusted OR 0.91, 95% CI 0.84 to
0.99). To explore further the association between heart
failure and use of glucocorticoids, we stratified according to
daily dose.
There was a dose–response relation between daily dose and
risk of heart failure among current users of oral glucocorti-
coids (adjusted OR 1.95, 95% CI 1.72 to 2.21 for low dose
(, 7.5 mg prednisolone equivalent daily dose); adjusted OR
2.27, 95% CI 2.00 to 2.59 for medium dose (7.5–20 mg
prednisolone equivalent daily dose); and adjusted OR 3.69,
95% CI 3.26 to 4.18 for high dose (. 20 mg prednisolone
equivalent daily dose). Stratification according to history of
cardiovascular drug use showed that the stratum specific ORs
were similar for patients with and those without a history of
cardiovascular drug use and use of antidiabetic drugs (data
not shown).
To explore the possibility that certain covariates differed
between users and non-users, a logistic regression model was
fitted with use of glucocorticoids as dependent variable and
patient characteristics, health care utilisation, and use of
prescription drugs as independent variables. We found that
patients using antidiabetic drugs were less likely to use oral
glucocorticoids (OR 0.61, 95% CI 0.56 to 0.67).
Current use of oral glucocorticoids was associated with
heart failure in all groups: the RA matched group, the COPD
matched group, and the non-RA/non-COPD matched group
(table 4). However, the relation was strongest in the COPD
group. For ischaemic heart disease, current use of oral
glucocorticoids was similarly increased in the RA matched
group and the COPD matched group. In the group of patients
Table 2 Exposure to oral glucocorticoids among cases (n =50656) and controls
(n = 50656) and risk of any cardiovascular or cerebrovascular event
Exposure Cases (n = 50 656)
Controls
(n = 50 656) Crude OR (95% CI) Adjusted OR (95% CI)*
Ever used oral glucocorticoids
Yes 15 355 (30.3%) 13 395 (26.4%) 1.31 (1.27 to 1.35) 1.25 (1.21 to 1.29)
Timing of oral glucocorticoid use
Current use 8 167 (16.1%) 6 015 (11.9%) 1.56 (1.50 to 1.62) 1.48 (1.41 to 1.54)
Recent use 3 491 (6.9%) 3 681 (7.3%) 1.08 (1.02 to 1.14) 1.03 (0.98 to 1.09)
Past use 3 697 (7.3%) 3 699 (7.3%) 1.12 (1.06 to 1.18) 1.08 (1.02 to 1.14)
Current users of oral glucocorticoids (average daily dose in mg prednisolone equivalents)
,7.5 mg/day 2 211 (4.5%) 1 710 (3.4%) 1.46 (1.36 to 1.57) 1.44 (1.34 to 1.55)
7.5–20 mg/day 2 015 (4.1%) 1 627 (3.3%) 1.37 (1.28 to 1.48) 1.30 (1.21 to 1.40)
>20 mg 2 593 (5.3%) 1 735 (3.5%) 1.73 (1.62 to 1.86) 1.63 (1.52 to 1.75)
Quartiles of cumulative dose (in mg prednisolone equivalents)
,500 mg 1 925 (4.4%) 1 362 (3.2%) 1.58 (1.45 to 1.73) 1.61 (1.38 to 1.88)
500–1810 mg 2 047 (4.7%) 1 605 (3.7%) 1.39 (1.28 to 1.51) 1.34 (1.16 to 1.54)
1810–5418 mg 2 006 (4.6%) 1 649 (3.8%) 1.36 (1.26 to 1.47) 1.19 (1.03 to 1.37)
.5418 mg 2 009 (4.6%) 1 277 (3.0%) 1.71 (1.57 to 1.86) 1.56 (1.35 to 1.80)
*Adjusted for use of NSAIDs, HRT, antihypertensive drugs, nitrates, oral anticoagulants, antiplatelet drugs,
antidiabetic drugs, bronchodilators, cromoglycates, inhaled glucocorticoids, DMARDs, smoking, and BMI.
Table 3 Use of oral glucocorticoids and cardiovascular or cerebrovascular events,
stratified according to type of outcome event
Outcome event Cases (n = 50656) Controls (n = 50656) Crude OR (95% CI) Adjusted OR (95% CI)*
Ischaemic heart disease
Ever used oral glucocorticoids
Yes 5 298 (25.6%) 4 956 (24.0%) 1.13 (1.08 to 1.20) 1.09 (1.03 to 1.15)
Timing of oral glucocorticoid use
Current use 2 507 (12.1%) 2 115 (20.2%) 1.26 (1.18 to 1.35) 1.20 (1.11 to 1.29)
Recent use 1 310 (6.3%) 1 422 (6.9%) 0.98 (0.90 to 1.06) 0.93 (0.85 to 1.02)
Past use 1 481 (7.2%) 1 419 (6.9%) 1.10 (1.01 to 1.19) 1.07 (0.98 to 1.17)
Heart failure
Ever used oral glucocorticoids
Yes 6 401 (44.4%) 4 763 (33.1%) 2.00 (1.88 to 2.12) 1.91 (1.79 to 2.03)
Timing of oral glucocorticoid use
Current use 4 020 (27.9%) 2 209 (15.3%) 2.77 (2.57 to 2.97) 2.66 (2.46 to 2.87)
Recent use 1 299 (9.0%) 1 315 (9.1%) 1.48 (1.35 to 1.62) 1.40 (1.27 to 1.55)
Past use 1 082 (7.5%) 1 239 (8.6%) 1.23 (1.12 to 1.36) 1.19 (1.08 to 1.32)
Stroke/transient ischaemic attack
Ever used oral glucocorticoids
Yes 3 656 (23.4%) 3 676 (23.6%) 0.99 (0.93 to 1.05) 0.95 (0.89 to 1.01)
Timing of oral glucocorticoid use
Current use 1 640 (10.5%) 1 691 (10.8%) 0.96 (0.89 to 1.04) 0.91 (0.84 to 0.99)
Recent use 882 (5.7%) 944 (6.1%) 0.93 (0.84 to 1.03) 0.89 (0.80 to 0.99)
Past use 1 134 (7.3%) 1 041 (6.7%) 1.09 (0.99 to 1.20) 1.06 (0.96 to 1.17)
*Adjusted for use of NSAIDs, HRT, antihypertensive drugs, nitrates, oral anticoagulants, antiplatelet drugs,
antidiabetic drugs, bronchodilators, cromoglycates, inhaled glucocorticoids, DMARDs, smoking, and BMI.
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without RA and lung disease, use of oral glucocorticoids was
not significantly associated with ischaemic heart disease
(adjusted OR 1.09, 95% CI 0.96 to 1.22). There was no
association between oral glucocorticoid use and cerebrovas-
cular events in any of the case–control patient subgroups.
DISCUSSION
This large nested case–control study addressed specifically
the risk of cardiovascular and cerebrovascular disease
associated with oral glucocorticoid treatment. This study
shows that, in a cohort of patients receiving glucocorticoid by
some route, those receiving prescriptions for oral glucocorti-
coid have a 25% higher risk of cardiovascular disease than
patients with non-oral, non-systemic glucocorticoids after
adjusting for confounders. The OR was higher among cur-
rent users of oral glucocorticoids and patients taking the
highest dose. The increased use of oral corticosteroids was
greatest for patients with heart failure, was less obvious for
patients with ischaemic heart disease, and was not apparent
for patients with cerebrovascular disease. Moreover, the
increased proportion of current oral glucocorticoid use among
patients with cardiovascular disease was observed in patients
with different underlying disease indications for glucocorti-
coid treatment, although it was greater among patients with
COPD than among patients with RA or other diseases.
Therefore, we found a relatively small but significant increase
in risk of cardiovascular events among patients at a high
baseline risk. Given the high prevalence of glucocorticoid use
in the general population, the number needed to harm—that
is, the number of patients needed to be treated with
glucocorticoids for one additional outcome event to occur—
is clinically relevant.
The way cases and controls were identified means that
some caution is required in the interpretation of the
magnitude of these associations. To ensure active registration
of each case in the GPRD and hence to ensure complete
outcome data, all participants had to have received at least
one prescription during the study period. To minimise bias
we chose to compare patients receiving oral glucocorticoids
with patients receiving topical glucocorticoids. This means
that the estimates in this study reflect a comparison of oral
glucocorticoid use with glucocorticoid use by another route,
not with non-use of glucocorticoids. Since topical (when
frequently used) and inhaled glucocorticoids may also exhibit
systemic effects, this approach may slightly underestimate
associations with glucocorticoid treatment. Estimation of
glucocorticoid exposure is not straightforward, however,
since glucocorticoid treatment for chronic disease is typically
intermittent over many years. Cumulative dose in intermit-
tent users is difficult to estimate because prescriptions may
not always be recorded—for example, if short courses of
drugs are issued during hospital admissions—and because
the average time between start of follow up and the index
date was only about three years. We therefore believe that the
best indicator of exposure is the current dose being prescribed
to patients who are current users in the three months leading
up to their index date; these patients are most likely to be
receiving chronic glucocorticoid treatment. Indeed, we found
that current users were those patients with the highest
number of prescriptions during follow up and who had the
highest cumulative dose compared with non-current users of
glucocorticoids. In the group of current users we found the
strongest associations with cardiovascular disease together
with evidence of a dose–response relation.
The ascertainment of cases and controls is also subject to
misclassification. All outcome events are related to incident
diagnoses. There could have been misclassification with
respect to diagnoses of study outcomes but this is likely to be
non-differential between cases and controls for cardiovas-
cular and cerebrovascular events. As fluid retention is a
known side effect of glucocorticoid use, we cannot exclude
the possibility that diagnostic suspicion bias accounts for part
of the observed effect for heart failure.
Further, risk factors for cardiovascular disease may be
identified and treated more readily among patients being
prescribed glucocorticoids. Finally, smoking is more common
among patients with COPD and RA and may explain an
apparent association between glucocorticoid treatment
and cardiovascular disease. To account for these potential
confounders, ORs were adjusted for all relevant drug
prescriptions and for BMI and smoking. These adjustments
had only modest effects on the estimates, suggesting that the
Table 4 Use of oral glucocorticoids and cardiovascular or cerebrovascular events
stratified by disease indication: rheumatoid arthritis (RA, n = 1515), chronic obstructive
pulmonary disease (COPD, n = 16440), other (n = 31240)
Adjusted OR (95% CI)
RA cohort* COPD cohort Other cohort
All outcomes
Timing of oral glucocorticoid use
Current use 1.37 (1.16 to 1.62) 1.68 (1.57 to 1.80) 1.13 (0.99 to 1.29)
Recent use 1.28 (0.98 to 1.68) 1.06 (0.98 to 1.15) 1.12 (0.92 to 1.35)
Past use 1.17 (0.87 to 1.58) 1.08 (1.00 to 1.16) 1.13 (0.95 to 1.33)
Ischaemic heart disease events
Timing of oral glucocorticoid use
Current use 1.36 (1.02 to 1.81) 1.28 (1.06 to 1.55) 1.09 (0.96 to 1.22)
Recent use 1.09 (0.67 to 1.77) 0.94 (0.77 to 1.14) 0.97 (0.81 to 1.17)
Past use 1.34 (0.82 to 2.19) 1.05 (0.87 to 1.26) 1.12 (0.95 to 1.32)
Heart failure
Timing of oral glucocorticoid use
Current use 1.55 (1.16 to 2.07) 3.03 (2.69 to 3.40) 1.89 (1.65 to 2.16)
Recent use 1.52 (0.98 to 2.33) 1.39 (1.22 to 1.58) 1.38 (1.10 to 1.74)
Past use 1.12 (0.69 to 1.84) 1.14 (1.00 to 1.30) 1.42 (1.14 to 1.77)
Stroke/transient ischaemic attack
Timing of oral glucocorticoid use
Current use 1.23 (0.92 to 1.64) 0.81 (0.71 to 0.93) 1.03 (0.92 to 1.16)
Recent use 1.23 (0.73 to 2.08) 0.88 (0.76 to 1.02) 0.93 (0.77 to 1.13)
Past use 1.07 (0.60 to 1.91) 1.00 (0.87 to 1.16) 1.29 (1.09 to 1.53)
*Adjusted for use antidiabetic drugs, cardiovascular drugs, NSAIDs, DMARDs, and history or treatment of lung
diseases; adjusted for use of antidiabetic drugs, cardiovascular drugs, NSAIDs, number of general practitioner
visits, BMI, and smoking.
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associations between cardiovascular disease and oral gluco-
corticoid use are independent of these confounders in this
study.
A major methodological concern in observational studies
arises from the lack of random allocation of patients to use
oral glucocorticoids and hence the potential for confounding
by indication.27 As both RA and COPD are associated with
cardiovascular morbidity and mortality, the underlying
disease, rather than exposure to glucocorticoids, may explain
the observed association. To address this issue, we examined
the consistency of the association between oral glucocorticoid
use and cardiovascular disease among patients with different
underlying diseases: cases and controls were matched
according to the presence of RA, COPD, or the absence of
either condition.
The results may also be biased due to confounding by
disease severity, as patients using oral glucocorticoids are
likely to be more severely affected by the underlying disease.
Thus, we adjusted for use of other disease modifying drugs
that reflect, at least in part, disease activity in RA. Duration of
disease was not a confounder in this study.
Finally, the use of glucocorticoids in RA, COPD, and other
conditions may be different. The most frequent indications
for oral glucocorticoid treatment besides RA and COPD are
skin, neurological, and gastrointestinal tract diseases,1 in
which patterns of prescription may differ from those in RA
and COPD.
Despite these limitations, the results in table 4 show
associations between oral glucocorticoid prescription and
cardiovascular disease in all groups and show interesting
differences between groups. Among patients with COPD, use
of oral glucocorticoids was associated more strongly with
heart failure than with ischaemic heart disease. Among
patients with RA, heart failure and ischaemic heart disease
were similarly associated with oral glucocorticoid use. Among
patients with neither RA nor COPD, only heart failure was
significantly associated with oral glucocorticoid treatment.
These data suggest that there is an interaction between the
associations of cardiovascular outcome and the underlying
disease indication or oral glucocorticoid use, but that both
have independent effects.
In all of our analyses, use of oral glucocorticoids was most
strongly associated with heart failure. Associations with
ischaemic heart disease events were relatively weak and there
were no associations with cerebrovascular disease. Sodium
retention and increase in extracellular fluid are well known
side effects of glucocorticoids and may be responsible for
precipitating diagnosis, particularly in patients with cor
pulmonale caused by COPD. However, the association
between oral glucocorticoid treatment and heart failure was
also present among patients with as well as those without
COPD who had not received a recorded prescription for
glucocorticoids for more than a year before diagnosis, long
after any sodium retaining effect would have corrected itself.
We can only speculate on the mechanism for this, although it
may involve actions of corticosteroids on cardiac remodelling
and fibrosis.
Our hypothesis a priori was that oral glucocorticoid use
would predict ischaemic heart disease events and strokes
because glucocorticoids adversely affect long term risk factors
including obesity, blood pressure, plasma lipids, and glucose.
However, adjustment for body mass index and antihyperten-
sive, lipid lowering, and hypoglycaemic medications did not
substantially attenuate the association between oral gluco-
corticoid treatment and cardiovascular outcomes. It may be
that the risk factors mediating adverse effects of glucocorti-
coids were not adequately treated in many patients or that
subtle changes in risk factors occurred that were insufficient
to cause practitioners to initiate treatment but were sufficient
to adversely affect outcome. These explanations do not,
however, explain the discrepancy between associations of
oral glucocorticoid use and occlusive disease in the coronary
and cerebrovascular circulation. For patients with stroke and
transient ischaemic attack, oral glucocorticoid treatment was
associated with a protective effect (table 3). This suggests
that the mechanisms linking glucocorticoid use and cardio-
vascular outcome are complex, perhaps reflecting a balance
between adverse and potentially protective effects. However,
there is also evidence suggesting that patients cured of
Cushing’s disease still have an increased prevalence of
atherosclerosis and maintain cardiovascular risk factors of
the active disease, possibly due to residual obesity, insulin
resistance syndrome, or both.28 29
Our results raise the possibility that general practitioners
avoid prescribing oral glucocorticoids to patients with
established cardiovascular risk factors. There were no striking
differences between users and non-users of oral glucocorti-
coids, except that patients with diabetes were less likely to
have been prescribed oral glucocorticoids. However, diabetes
was adjusted for in the multivariate analyses.
Summary
This large study identified oral glucocorticoid use as a risk
factor for heart failure and ischaemic heart disease.
Physicians should be aware of the negative vascular effect
of glucocorticoids and add this knowledge in balancing
positive and negative effects for the individual patient when
considering to prescribe glucocorticoids, especially to patients
with cardiovascular risk factors. However, this evidence
remains observational and only a randomised controlled trial
of glucocorticoid treatment versus other disease modifying
agents is likely to distinguish the importance of the under-
lying disease activity from its treatment in predicting
cardiovascular outcome.
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Septic emboli from aortic valve endocarditis
A
21 year old man, with a history of tissue aortic valve
replacement for aortic regurgitation secondary to
bicuspid aortic valve, and with good dental hygiene,
presented with a four week history of malaise, nausea,
anorexia, and fever. In the week preceding hospital admis-
sion, he started having abdominal pain.
Physical examination revealed pyrexia, tachycardia, one
splinter haemorrhage, soft systolic murmur, a tender left
hypochondrium with no rebound or guarding, and good
bowel sounds. Initial investigations showed a raised white
cell count of 206109/l, C reactive protein of 300 mg/dl,
normal renal function, and three sets of blood cultures which
grew Streptococcus viridans. He had a transoesophageal
echocardiogram which did not show vegetations but there
were features suggestive, but not typical, of aortic root
abscess. The patient was treated with benzyl penicillin and
gentamicin.
In view of the abdominal pain, he had an abdominal x ray,
which showed dilated small and large bowels. A computed
tomographic (CT) scan of the abdomen showed splenic
infarcts and renal emboli (upper and lower panels), in
keeping with septic emboli.
The patient underwent aortic valve replacement the next
day. An aortic root abscess was evident. He had an
uncomplicated recovery from his surgery and his abdominal
complications resolved, without any further intervention. He
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